Table 3. Distribution of LMP2/LMP7 genotypes in each study group.
| Genotypes | Controls [n (%)] | Spontaneous clearance [n (%)] | Persistent infection [n (%)] | Controls/Persistent infection |
Controls/Spontaneous clearance |
Persistent infection/Spontaneous clearance |
||||
| P* | OR(95%CI)* | P* | OR(95%CI)* | P* | OR(95%CI)* | |||||
| LMP2 | ||||||||||
| Arg/Arg | 140(62.2) | 113(59.8) | 112(64.7) | — | l.00(reference) | — | l.00(reference) | — | l.00(reference) | |
| Arg/His | 77(34.2) | 69(36.5) | 52(30.1) | 0.362 | 0.79(0.48-1.31) | 0.947 | 1.02(0.62-1.66) | 0.181 | 0.73(0.47-1.16) | |
| His/His | 8(3.6) | 7 (3.7) | 9(5.2) | 0.497 | 1.53(0.45-5.19) | 0.991 | 0.99(0.27-3.71) | 0.995 | 0.99(0.35-2.85) | |
| Arg/His+His/His | 85(37.8) | 76(40.2) | 61(35.3) | 0.505 | 0.85(0.52-1.38) | 0.952 | 1.02(0.63-1.63) | 0.217 | 0.76(0.49-1.18) | |
| LMP7 | ||||||||||
| Gln/Gln | 155(68.9) | 112(59.3) | 80(46.2) | — | l.00(reference) | — | l.00(reference) | — | l.00(reference) | |
| Gln/Lys | 61(27.1) | 65(34.4) | 73(42.2) | 0.029 | 1.75(1.06-2.90) | 0.810 | 1.07(0.64-1.77) | 0.032 | 1.64(1.04-2.57) | |
| Lys/Lys | 9(4.0) | 12(6.3) | 20(11.6) | 0.017 | 3.16(1.23-8.12) | 0.343 | 1.68(0.57-4.97) | 0.030 | 2.40(1.09-5.28) | |
| Gln/Lys+Lys/Lys | 70(31.1) | 77(40.7) | 93(53.8) | 0.006 | 1.94(1.21-3.12) | 0.604 | 1.14 (0.70-1.85) | 0.010 | 1.76(1.15-2.69) | |
* Logistic regression model, adjusted by gender, age, injection drug user and duration of drug use.